PGK1 and melanoma: This is in line with the results previously reported for LDC in different cell types, whereby this drug inhibited glycolysis by interfering with membrane hexose transporters [42], inducing a dose-dependent detachment of glycolytic enzymes (phosphofructokinase and aldolase) from the cytoskeleton of B16 melanoma cells [43], or causing oxidative damage to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and phosphoglycerate kinase (PGK1) [44].